Alexion ( Alexion )

Alexion

Alexion's picture

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.

Alexion press release, blog etc

01/02/2018 - 15:36 Alexion and Elliott Agree to Collaborate on Identifying a New Board Member
12/26/2017 - 04:49 Soliris (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)
12/11/2017 - 10:29 Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting
11/09/2017 - 05:51 Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service
11/08/2017 - 16:33 Alexion Appoints Francois Nader, M.D. to its Board of Directors
11/06/2017 - 08:11 Alexion Receives New Japanese Patent for Soliris (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio
11/03/2017 - 04:11 New Interim Data Presented at NASPGHAN 2017 Meeting Show Survival Beyond 1 Year of Age in Infants with LAL-D Treated with Kanuma (sebelipase alfa)
11/01/2017 - 08:25 New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting
10/23/2017 - 16:18 FDA Approves Soliris (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)
09/14/2017 - 18:11 Alexion Adds Paul A. Friedman, M.D. to Its Board of Directors
09/13/2017 - 14:28 Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis
09/12/2017 - 11:59 Alexion Announces Restructuring to Advance Corporate Strategy
08/21/2017 - 08:05 European Commission Grants New Indication for Soliris (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)
08/15/2017 - 12:29 Alexion Receives Three New U.S. Patents for Soliris (eculizumab), Extending Patent Protection Into 2027
08/10/2017 - 05:26 Alexion and Sema4 Partner in Rare Disease Diagnostics and Systems Biology
07/05/2017 - 03:00 Alexion Reaches Funding Agreement with NICE and NHS England for Strensiq (asfotase alfa) for Patients with Pediatric-onset Hypophosphatasia (HPP)
06/22/2017 - 18:43 Alexion Receives Positive CHMP Opinion for Soliris (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union
06/12/2017 - 20:14 Alexion Names Paul Clancy Chief Financial Officer